Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction
A double-blind randomized active-controlled clinical trial that will determine the efficacy of R-propafenone for suppressing inducible atrial fibrillation in patients with a history of paroxysmal AF undergoing ablation. This is a single center study conducted at Vanderbilt University Medical Center by VanCART members Knollmann and Shoemaker.
Arrhythmia Genetics Network (AGENT) - Vanderbilt Cohort
Multicenter observational registry and DNA biorepository for inherited arrhythmia syndromes. Currently participating centers: Vanderbilt, MGH, U of Washington, Stanford, Cedars Sinai.
GS-6615 Late Sodium Current Blocker for Long QT Type 3
Phase 3 clinical trial of GS-6615 to reduce QT interval in LQT3 patients. This is a study conducted at Vanderbilt University by VanCART member M. Benjamin Shoemaker, MD, MSCI.
Sudden Unexplained Death DNA/Tissue Repository
Post-mortem DNA and tissue biorepository of victims of sudden unexplained death or evidence of arrhythmogenic cardiomyopathy. Collaboration with local medical examiner
Multicenter observational study of activity level (measured by Fitbit) and arrhythmic events in LQTS (PI: Rachel Lampert (Yale) http://livelqts.org/ )
Observational registry and DNA biorepository for patients with inherited cardiomyopathies seen in the VUH Inherited Arrhythmia Clinic.
Multicenter observational study of activity level (measured by a Fitbit) and arrhythmic events in HCM (PI: Rachel Lampert (Yale) http://livehcm.org/ )
HCM Pacing Study
Prospective study of QT response to cardiac pacing interval in patients with HCM versus controls. Performed in CRC.
Phase 3 clinical trial of GS-6615 late sodium current blocker to improve peak VO2 in HCM (measured at baseline and 24 weeks)
Arrhythmia and Cardiomyopathy Phenotypes from eMERGE-3 (Electric Medical Records and Genomics Networks)
A current project of the eMERGE network that will study the issue surrounding the return-of-result to providers of incidentally detected, potentially pathogenic mutations including those found in arrhythmia and cardiomyopathy associated genes.
A New Paradigm for Identifying Patients and Drugs at Risk for QT Prolongation (Improving Prediction of Drug Action- PGRN IV
A current project of PGRN that will create iPSC-derived cardiomyocytes from patients with a history of drug-induced TdP.
The Vanderbilt AF Electrophysiology Phenotyping Project
A prospective observational registry with DNA and EP data from patients with AF undergoing AF ablation. Standardized data collection includes: baseline intervals, AV block cycle length, AV node ERP, LA ERP, pulmonary vein ERP, LA voltage, LA conduction velocity, and PV myocardial sleeve measurements.
Prospective Identification of Long QT Syndrome in Fetal Life
This study is a multicenter, international, observational study lead by Dr. Bettina Cuneo, University of Colorado and Dr. Peter Schwartz, Milan Italy. The research aim is to identify individuals prior to birth who have long QT syndrome (LQTS). Visit the sudy website at